Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use
bFGF Treatment and Represent a Superb Tool for
Immunosuppressive Clinical Applications

J 2020

Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications

TESAŘOVÁ, Lenka, Klára JAREŠOVÁ, Pavel ŠIMARA a Irena KOUTNÁ

Základní údaje

Originální název

Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications

Autoři

TESAŘOVÁ, Lenka (203 Česká republika, garant, domácí), Klára JAREŠOVÁ (203 Česká republika, domácí), Pavel ŠIMARA (203 Česká republika, domácí) a Irena KOUTNÁ (203 Česká republika, domácí)

Vydání

International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2020, 1422-0067

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.923

Kód RIV

RIV/00216224:14110/20:00116470

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/ijms21155366

UT WoS

000567132000001

Klíčová slova anglicky

mesenchymal stem cells; umbilical cord; advanced therapy medicinal product; immunosuppression

Štítky

14110517, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 7. 2021 10:28, Mgr. Tereza Miškechová

Anotace

V originále

Mesenchymal stem cells (MSCs) have become a promising tool in cellular therapy for restoring immune system haemostasis; however, the success of clinical trials has been impaired by the lack of standardized manufacturing processes. This study aims to determine the suitability of source tissues and culture media for the production of MSC-based advanced therapy medicinal products (ATMPs) and to define parameters to extend the set of release criteria. MSCs were isolated from umbilical cord (UC), bone marrow and lipoaspirate and expanded in three different culture media. MSC phenotype, proliferation capacity and immunosuppressive parameters were evaluated in normal MSCs compared to primed MSCs treated with cytokines mimicking an inflammatory environment. Compared to bone marrow and lipoaspirate, UC-derived MSCs (UC-MSCs) showed the highest proliferative capacity, which was further enhanced by media supplemented with bFGF, while the cells maintained their immunosuppressive characteristics. Moreover, UC-MSCs expanded in the bFGF-enriched medium were the least sensitive to undesirable priming-induced changes in the MSC phenotype. Surface markers and secreted factors were identified to reflect the cell response to inflammatory priming and to be variable among MSCs from different source tissues. This study demonstrates that UC is a favorable cell source for manufacturing MSC-based ATMPs for immunosuppressive applications. UC-MSCs are able to use the bFGF-enriched medium for higher cell yields without the impairment of immunosuppressive parameters and undesirable phenotype changes after inflammatory preconditioning of MSCs before transplantation. Additionally, immunosuppressive parameters were identified to help finding predictors of clinically efficient MSCs in the following clinical trials.

Návaznosti

LM2018128, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Český národní uzel Evropské sítě infrastruktur klinického výzkumu (CZECRIN)

Citovat

TESAŘOVÁ, Lenka, Klára JAREŠOVÁ, Pavel ŠIMARA a Irena KOUTNÁ. Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2020, roč. 21, č. 15, s. 1-27. ISSN 1422-0067. Dostupné z: https://dx.doi.org/10.3390/ijms21155366.

@article{1680205,
   author = {Tesařová, Lenka and Jarešová, Klára and Šimara, Pavel and Koutná, Irena},
   article_location = {Basel},
   article_number = {15},
   doi = {http://dx.doi.org/10.3390/ijms21155366},
   keywords = {mesenchymal stem cells; umbilical cord; advanced therapy medicinal product; immunosuppression},
   language = {eng},
   issn = {1422-0067},
   journal = {International Journal of Molecular Sciences},
   title = {Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications},
   url = {https://www.mdpi.com/1422-0067/21/15/5366},
   volume = {21},
   year = {2020}
}

TY  - JOUR
ID  - 1680205
AU  - Tesařová, Lenka - Jarešová, Klára - Šimara, Pavel - Koutná, Irena
PY  - 2020
TI  - Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications
JF  - International Journal of Molecular Sciences
VL  - 21
IS  - 15
SP  - 1-27
EP  - 1-27
PB  - Multidisciplinary Digital Publishing Institute
SN  - 14220067
KW  - mesenchymal stem cells
KW  - umbilical cord
KW  - advanced therapy medicinal product
KW  - immunosuppression
UR  - https://www.mdpi.com/1422-0067/21/15/5366
L2  - https://www.mdpi.com/1422-0067/21/15/5366
N2  - Mesenchymal stem cells (MSCs) have become a promising tool in cellular therapy for restoring immune system haemostasis; however, the success of clinical trials has been impaired by the lack of standardized manufacturing processes. This study aims to determine the suitability of source tissues and culture media for the production of MSC-based advanced therapy medicinal products (ATMPs) and to define parameters to extend the set of release criteria. MSCs were isolated from umbilical cord (UC), bone marrow and lipoaspirate and expanded in three different culture media. MSC phenotype, proliferation capacity and immunosuppressive parameters were evaluated in normal MSCs compared to primed MSCs treated with cytokines mimicking an inflammatory environment. Compared to bone marrow and lipoaspirate, UC-derived MSCs (UC-MSCs) showed the highest proliferative capacity, which was further enhanced by media supplemented with bFGF, while the cells maintained their immunosuppressive characteristics. Moreover, UC-MSCs expanded in the bFGF-enriched medium were the least sensitive to undesirable priming-induced changes in the MSC phenotype. Surface markers and secreted factors were identified to reflect the cell response to inflammatory priming and to be variable among MSCs from different source tissues. This study demonstrates that UC is a favorable cell source for manufacturing MSC-based ATMPs for immunosuppressive applications. UC-MSCs are able to use the bFGF-enriched medium for higher cell yields without the impairment of immunosuppressive parameters and undesirable phenotype changes after inflammatory preconditioning of MSCs before transplantation. Additionally, immunosuppressive parameters were identified to help finding predictors of clinically efficient MSCs in the following clinical trials.
ER  -

TESAŘOVÁ, Lenka, Klára JAREŠOVÁ, Pavel ŠIMARA a Irena KOUTNÁ. Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications. \textit{International Journal of Molecular Sciences}. Basel: Multidisciplinary Digital Publishing Institute, 2020, roč.~21, č.~15, s.~1-27. ISSN~1422-0067. Dostupné z: https://dx.doi.org/10.3390/ijms21155366.

Podrobný výpis o publikaci